A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps | MicrobiomeTrials
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2024-12-16Est. Completion: 2026-03-31
Enrollment target: 66 participants
Locations
Allervie Clinical Research - Birmingham- Site Number : 8400006, Birmingham, Alabama, United States
Modena Allergy + Asthma- Site Number : 8400005, La Jolla, California, United States
United Medical Doctors - Murrieta- Site Number : 8400001, Murrieta, California, United States
Sacramento Ear Nose & Throat - Roseville- Site Number : 8400008, Roseville, California, United States
Western States Clinical Research- Site Number : 8400009, Wheat Ridge, Colorado, United States
Advanced Research Associates (ARA) Professionals- Site Number : 8400002, Miami, Florida, United States
Treasure Valley Medical Research- Site Number : 8400022, Boise, Idaho, United States
ENT Associates of Texas - McKinne- Site Number : 8400013, McKinney, Texas, United States
Alamo ENT Associates- Site Number : 8400026, San Antonio, Texas, United States
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400007, Norfolk, Virginia, United States
Investigational Site Number : 0320003, San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site Number : 0320001, Buenos Aires, Argentina
Investigational Site Number : 0320004, Corrientes, Argentina
Other microbiome trials you might be interested in